Anisoplin proteins as innovative biocontrol agents against pest invertebrates
Anisoplin proteins, derived from Metarhizium anisopliae, offer a novel biocontrol approach against insect pests. With toxic and antifeeding properties, they present a potential alternative to Bt toxins when incorporated into crops.
Overview
Anisoplin proteins are emerging as a novel class of biocontrol agents targeting pest invertebrates. Derived from the entomopathogenic fungus Metarhizium anisopliae, these proteins exhibit toxic and antifeeding properties against insects, potentially expanding the toolkit available for agricultural pest management. Unlike traditional biocontrol methods, anisoplin proteins may be naturally expressed in plants, offering a promising alternative or supplement to Bt toxins for enhanced crop protection.
Technical specifications
Anisoplin is structurally similar to restrictocin, known for its insecticidal properties. The hypothesis is supported by genome mining, which identified anisoplin-like genes in other fungi, suggesting a broad-spectrum insecticidal potential. Future validation will involve insect bioassays using recombinant anisoplin proteins, with assessments of insect mortality, growth, and feeding behavior. Proteomics and in silico analyses will ensure recombinant proteins reflect native structures, potentially enabling the development of genetically modified crops expressing anisoplin.
Technology readiness level
Currently at Technology Readiness Level 3, anisoplin proteins have undergone initial research and development, with ongoing efforts to validate their insecticidal activity through bioassays and proteomics analysis. This stage involves proof of concept and early experimental validation.
About Nova Southeastern University
Nova Southeastern University is a comprehensive private R1 research university in Fort Lauderdale–Davie with a strong professional focus and a multi‑campus footprint. Industry partners can access shared core facilities, wet/dry labs, and leasable space in the 215,000‑sq‑ft Center for Collaborative Research, enabling co‑located projects and streamlined compliance. An oceanographic campus at the entrance to Port Everglades provides direct field access and specialized facilities, while NSU Health and the adjacent HCA Florida University Hospital support clinical research and translation. Research is supported by competitive federal funding, including NIH and NOAA, alongside other federal sources such as DoD; a dedicated Office of Technology Transfer and Commercialization assists with IP, licensing, and startup formation.
Inquire about this partnering listing
Looking for
Industry applications
delivered to your inbox.